Hon. Judith G. Seidman: Honourable senators, I rise today to speak to Bill C-10, An Act respecting certain measures related to COVID-19, at third reading.

Just to remind us once again, the passage of Bill C-10 would give authority to the Minister of Health to make payments of up to $2.5 billion out of the Consolidated Revenue Fund in relation to COVID-19 tests. It would also allow the Minister of Health to transfer the COVID-19 tests to the provinces, territories and other establishments.

During my speech at second reading in this chamber, I raised a number of concerns with regard to Bill C-10. First and foremost, the lack of a provision for parliamentary oversight in this bill. You might remember the conversation that I had with Senator Lankin when she specifically asked me about my concerns and said that if there was one or two particular issues that I was concerned about, which ones would I recommend in amending this bill. You are going to hear that right now.

Honourable colleagues, as some of you may know, during the debate on Bill C-10 in the other place, the Minister of Health made a verbal commitment to report to both houses of Parliament every six months on the procurement, distribution and use of rapid antigen tests. At the Social Affairs, Science and Technology Committee meeting on Wednesday of this week, the minister reaffirmed and modified his commitment to present a report to Parliament every three months as opposed to every six months.

When asked by my colleague Senator Poirier what accounts for this change, the minister said:

That came from a reasonable request from the opposition party in the House of Commons. They said that six months is good but three months is better. We considered that request and felt that, in collaboration with provinces and territories, it would be even better to do it in that relatively shorter time period.

Honourable colleagues, parliamentary oversight is an integral component of our democracy. It allows for greater transparency when discussing the federal government’s policy objectives, especially when it concerns matters of public spending.

As the minister himself acknowledged Wednesday in committee, “. . . transparency is key in not only informing senators and members of Parliament but also informing Canadians.”

Including a provision in Bill C-10 for parliamentary oversight, as opposed to something that is just said in words, would ensure that the federal government is held accountable for its spending. It would allow us to monitor critical data that pertains to the cost, use and number of rapid antigen tests delivered to their final point-of-care settings. This is not only the purpose of good governance but also in our duty to be a chamber of sober second thought.

Honourable senators, that is why I am proposing an amendment to Bill C-10 to address this issue of accountability.

The amendment would ensure that the Minister of Health reports to Parliament every three months. It would also require the minister to report on federal spending incurred from the period of January 1, 2022, up until the date that Bill C-10 receives Royal Assent.

As written in clause 1 of Bill C-10, the Minister of Health may spend money out of the Consolidated Revenue Fund to account for any expenses incurred on or after January 1, 2022, in relation to COVID-19 tests. This is why parliamentary oversight is of utmost importance. This amendment would ensure that critical data does not go unreported to Parliament for indeterminate periods.